Citi analyst Yigal Nochomovitz raised the firm’s price target on Alpha Tau (DRTS) to $9 from $7 and keeps a Buy rating on the shares. The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s “broader-than-expected” Japan approval in head and neck cancer is leading to partnership opportunities, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Medical: U.S. Trial Expansion, Japan Approval, and Manufacturing Scale-Up Support Buy Rating Despite Near-Term Losses
- Alpha Tau Posts Wider 2025 Loss as Japanese Approval and U.S. Trial Progress Mark Pivotal Year
- Alpha Tau downgraded to Neutral from Overweight at Piper Sandler
- DRTS Earnings this Week: How Will it Perform?
- Alpha Tau Lands First International Approval as Japan Grants Marketing Clearance for Alpha DaRT (NASDAQ: DRTS)